Table 4.

The IC50 of anticancer drugs in CRC cell lines

	5FU	Oxaliplatin	CPT11
HCT116 cell line
mimic-NC	9.45 ± 1.86	11.49 ± 1.36	20.81 ± 3.18
miR933-mimic	4.82 ± 1.09	6.77 ± 0.74	5.39 ± 0.28
miR125b-2-3p-mimic	6.27 ± 0.58	9.69 ± 0.25	17.58 ± 0.59
inhibitor-NC	14.48 ± 3.23	18.70 ± 1.63	18.37 ± 0.25
miR933-inhibitor	19.70 ± 3.18	26.48 ± 1.50	30.26 ± 11.96
miR125b-2-3p-inhibitor	25.79 ± 1.60	29.10 ± 0.63	30.92 ± 4.40
DLD-1 cell line
mimic-NC	26.04 ± 10.09	13.29 ± 1.29	25.09 ± 5.51
miR933-mimic	18.59 ± 8.00	7.79 ± 1.16	20.28 ± 1.39
miR125b-2-3p-mimic	18.41 ± 1.85	9.07 ± 1.60	20.31 ± 0.42
inhibitor-NC	27.07 ± 1.46	15.82 ± 1.03	29.04 ± 2.28
miR933-inhibitor	65.49 ± 7.57	32.72 ± 1.66	48.41 ± 1.95
miR125b-2-3p-inhibitor	71.76 ± 3.99	50.42 ± 9.81	60.97 ± 9.56